Iovance Biotherapeutics, Inc.

999 Skyway Road
Suite 150
San Carlos
California
94070
United States

Tel: 650-260-7120

Email: Gen_Inq_Web@iovance.com

Show jobs for this employer

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.

HEADQUARTERS
999 Skyway Road
Suite 150
San Carlos, CA 94070
Phone: 650-260-7120
 
PHILADELPHIA
300 Rouse Blvd Navy Yard Corporate Center
Philadelphia, PA 19112

Stock Symbol: IOVA

190 articles with Iovance Biotherapeutics, Inc.